STADA Acquires Biopharma's Pharmaceutical Prescription and Consumer Health Business
December 12, 2019
The STADA Group agreed to acquire the pharmaceutical prescription and consumer health business of Ukrainian producer Biopharma, including GMP-certified production facilities in Bila Tserkva. The deal integrates Biopharma's pharma operations into STADA's European organization, expands STADA's local production footprint in Ukraine and is subject to Ukrainian merger control; Biopharma's shareholders will retain the company's plasma business.
- Buyers
- STADA Group
- Targets
- Biopharma (pharmaceutical prescription and consumer health business)
- Sellers
- Biopharma
- Industry
- Pharmaceuticals
- Location
- Kyiv Oblast, Ukraine
- Transaction Type
- Divestiture
Explore More
Related Acquisitions
-
PHINIA Acquires stoba Group
June 30, 2026
Manufacturing
PHINIA entered into a definitive agreement to acquire 100% of the equity interests of the stoba Group on June 30, 2026; the acquisition was completed on October 1, 2026. The deal adds stoba’s high-precision engineering and advanced manufacturing capabilities to PHINIA, broadening its reach across automotive, industrial, semiconductor, and aerospace and defense markets while strengthening supply chain resilience.
-
CapVest Acquires Majority Stake in STADA Arzneimittel
September 1, 2025
Healthcare Services
CapVest Partners LLP has completed its acquisition of a majority stake in STADA Arzneimittel AG, a global healthcare and pharmaceuticals company focused on consumer healthcare, generics, and specialty pharmaceuticals. CapVest and STADA plan to accelerate STADA’s global growth through both organic initiatives and strategic acquisitions.
-
Cooper Consumer Health Acquires Viatris' Over-the-Counter Business
July 3, 2024
Pharmaceuticals
Cooper Consumer Health has completed the acquisition of the Over-the-Counter (OTC) business of Viatris Inc., following regulatory approvals and worker council consultations. The deal brings more than 200 brands (including Betadine, Saugella, Armolipid and CB12), two manufacturing sites in Mérignac (France) and Confienza (Italy) and an R&D centre in Monza (Italy) into Cooper's platform, doubling Cooper's revenues to approximately €1.2bn.
-
Advent International and Warburg Pincus Acquire Baxter's BioPharma Solutions to Form Simtra BioPharma Solutions
October 2, 2023
Pharmaceuticals
Advent International and Warburg Pincus completed the acquisition of Baxter International's BioPharma Solutions (BPS) business for $4.25 billion in cash, creating a standalone CDMO named Simtra BioPharma Solutions. Simtra will operate manufacturing sites in Bloomington, Indiana and Halle, Germany, establish a corporate headquarters in New Jersey, and employ approximately 1,700 people to provide sterile contract manufacturing and parenteral delivery services to pharma and biotech customers.
-
Partners Group Acquires Pharmathen from BC Partners
July 19, 2021
Pharmaceuticals
Partners Group has agreed to acquire Pharmathen, the leading European drug delivery technology and pharmaceutical manufacturing company, from BC Partners in a transaction valued at approximately EUR 1.6 billion. The deal transfers control of Pharmathen to Partners Group (acting on behalf of its clients) and is aimed at supporting the company’s continued growth — including an intensified push into the US market — building on strong R&D and manufacturing capabilities.
-
STADA Acquires Walmark from MidEuropa
November 4, 2019
Consumer Products
STADA Arzneimittel AG has agreed to acquire Walmark a.s., a leading consumer healthcare company in Central Europe, from private equity firm MidEuropa Partners. The deal (consideration undisclosed) expands STADA's branded consumer health portfolio and strengthens its presence across Central and Eastern Europe; the transaction was expected to close in Q1 2020 subject to antitrust clearance.
Build a buyer list for your deal
Find active buyers from recent acquisition patterns and move straight into outreach.